Overview

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Status:
Not yet recruiting
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).
Phase:
Phase 3
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated